Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Stock Has Consensus Price Target of $7.67

Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $7.67.

PLYX has been the topic of several research analyst reports. HC Wainwright initiated coverage on Polaryx Therapeutics in a research note on Thursday, July 9th. They set a “buy” rating and a $7.00 target price on the stock. Wall Street Zen upgraded Polaryx Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Zacks Research raised Polaryx Therapeutics to a “hold” rating in a report on Friday, July 10th. Raymond James Financial started coverage on Polaryx Therapeutics in a research note on Thursday, August 13th. They set a “strong-buy” rating and a $6.00 price target on the stock. Finally, Weiss Ratings restated a “sell (e)” rating on shares of Polaryx Therapeutics in a report on Monday, September 28th.

Polaryx Therapeutics Price Performance

Shares of PLYX opened at $2.08 on Friday. The company has a 50 day moving average of $2.10 and a two-hundred day moving average of $3.26. Polaryx Therapeutics has a twelve month low of $1.85 and a twelve month high of $48.91. The company has a market cap of $103.69 million and a price-to-earnings ratio of -26.00.

Polaryx Therapeutics (NASDAQ:PLYX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. On average, sell-side analysts expect that Polaryx Therapeutics will post -0.22 EPS for the current year.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.